<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056573</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10144</org_study_id>
    <nct_id>NCT03056573</nct_id>
  </id_info>
  <brief_title>Assessment of the St Jude Medical Portico Resheathable Aortic Valve System-Alternative Access</brief_title>
  <acronym>Portico ALT</acronym>
  <official_title>Assessment of the St Jude Medical Portico Resheathable Aortic Valve System-Alternative Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Expand the indication of the Portico TF Delivery System and obtain approval of the
      Alternative Access Delivery System
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Expand the indication of the Portico TF Delivery System and obtain approval of the
      Alternative Access Delivery System to place a Portico transcatheter aortic valve through an
      alternative access site, specifically subclavian/axillary or transaortic (TAo) in subjects
      with symptomatic severe native aortic stenosis who are considered high surgical risk
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Actual">July 5, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Portico TF and ALT Delivery System</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Major Vascular Complications</measure>
    <time_frame>30 Days</time_frame>
    <description>Major Vascular complication is defined as
Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudo-aneurysm or
Access site or access-related vascular injury leading to death, life-threatening or major bleeding, visceral ischaemia or neurological impairment or
Distal embolization from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage or
The use of unplanned endovascular or surgical intervention associated with death, major bleeding, visceral ischaemia or neurological impairment or
Any new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram or
Surgery for access site-related nerve injury or
Permanent access site-related nerve injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of All- Cause Mortality</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All- Cause Mortality</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality</measure>
    <time_frame>30 Days</time_frame>
    <description>Any 1 of the following criteria:
Death due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, worsening heart failure)
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease.
All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure
All valve-related deaths including structural or nonstructural valve dysfunction or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Any 1 of the following criteria:
Death due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, worsening heart failure)
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease.
All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure
All valve-related deaths including structural or nonstructural valve dysfunction or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Disabling Stroke</measure>
    <time_frame>30 Days</time_frame>
    <description>Disabling stroke is an mRS score of 2 or more at 90 days and an increase of at least 1 mRS category from an individual's prestroke baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Disabling Stroke</measure>
    <time_frame>1 Year</time_frame>
    <description>Disabling stroke is an mRS score of 2 or more at 90 days and an increase of at least 1 mRS category from an individual's prestroke baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-disabling Strokes</measure>
    <time_frame>30 Days</time_frame>
    <description>Non-disabling is an mRS score of &lt;2 at 90 days or 1 that does not result in an increase of at least 1 mRS category from an individual's prestroke baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-disabling Strokes</measure>
    <time_frame>1 Year</time_frame>
    <description>Non-disabling is an mRS score of &lt;2 at 90 days or 1 that does not result in an increase of at least 1 mRS category from an individual's prestroke baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Life Threatening Bleeding Requiring Transfusion</measure>
    <time_frame>30 Days</time_frame>
    <description>Life threatening bleeding requiring transfusion
Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0 g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery AND
Does not meet criteria of life-threatening or disabling bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Life Threatening Bleeding Requiring Transfusion</measure>
    <time_frame>1 Year</time_frame>
    <description>Life threatening bleeding requiring transfusion
Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0 g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery AND
Does not meet criteria of life-threatening or disabling bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Kidney Injury Requiring Dialysis</measure>
    <time_frame>30 Days</time_frame>
    <description>Increase in serum creatinine to greater than or equal to 300% (3 X increase compared with baseline) or serum creatinine of ≥ 4.0 mg/dL (354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)or Urine output &lt;0.3 mL/kg per hour for ≥24 hours or anuria for ≥12 hours. Patients receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Kidney Injury Requiring Dialysis</measure>
    <time_frame>1 Year</time_frame>
    <description>Increase in serum creatinine to greater than or equal to 300% (3 X increase compared with baseline) or serum creatinine of ≥ 4.0 mg/dL (354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)or Urine output &lt;0.3 mL/kg per hour for ≥24 hours or anuria for ≥12 hours. Patients receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of Periprocedural Encephalopathy, All Stroke and All TIA</measure>
    <time_frame>30 Days</time_frame>
    <description>Stroke is an acute symptomatic episode of neurological dysfunction attributed to a vascular cause.
Transient Ischemic Attack (TIA) is a transient (less than 24 hrs) episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. No evidence of infarction if imaging performed.
Encephalopathy is defined as altered mental state (e.g., seizures, delirium, confusion, hallucinations, dementia, coma, psychiatric episode).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of Periprocedural Encephalopathy, All Stroke and All TIA</measure>
    <time_frame>1 Year</time_frame>
    <description>Stroke is an acute symptomatic episode of neurological dysfunction attributed to a vascular cause.
Transient Ischemic Attack (TIA) is a transient (less than 24 hrs) episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. No evidence of infarction if imaging performed.
Encephalopathy is defined as altered mental state (e.g., seizures, delirium, confusion, hallucinations, dementia, coma, psychiatric episode).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate and Severe Aortic Regurgitation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA Class From Baseline to 30 Days</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>New York Heart Association (NYHA) functional classification provides a way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina pain.
Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Six Minute Walk Test From Baseline as Compared to 30 Days</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>The Six Minute Walk Test (6MWT)measures the distance that a patient can walk in a period of 6 minutes. The distance walked is measured in meters. This test measures the patients' functional status. The more meters a patient can walk over baseline indicates improvement in functional status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Effective Orifice Area From Baseline as Compared to 30 Days</measure>
    <time_frame>Baseline to 30 days.</time_frame>
    <description>Effective Orifice Area of the prosthetic valve measured via echocardiography to determine physiological area of blood flow through the valve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Acute Device Success</measure>
    <time_frame>7 days</time_frame>
    <description>Acute device success is defined as a subject who achieves a) successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system, b) correct position of the device in the proper anatomical location, c) intended performance of the prosthetic heart valve, and d) only 1 valve implanted in the proper anatomical location.
Device success is a 'technical' composite endpoint meant to characterize the acute device and procedural factors which underlie vascular access, delivery, and performance of the TAVI system. Echocardiography should be routinely utilized as the standard for measuring prosthetic valve stenosis and regurgitation immediately after TAVI, and should always be performed in a resting state, either within 24-48 h after the index procedure or before hospital discharge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Subclavian/axillary</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subclavian/axillary access route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transaortic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transaortic access route</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transaortic TAVR Implant</intervention_name>
    <description>Transaortic TAVR implant</description>
    <arm_group_label>Transaortic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subclavian /Axillary TAVR implant</intervention_name>
    <description>Subclavian /Axillary TAVR implant</description>
    <arm_group_label>Subclavian/axillary</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has provided written informed consent prior to uploading CT scan to core lab.

          2. Subject is ≥ 18 years of age or legal age in host country.

          3. Subject's aortic annulus diameter meets the range indicated in the Instructions for
             Use as measured by multislice CT conducted within 180 days prior to the index
             procedure.

          4. Subject has senile degenerative aortic stenosis seen by echocardiography within 90
             days of index procedure as measured by:

               1. mean gradient &gt;40 mmHg

               2. Peak velocity ≥ 4.0 m/s

               3. Doppler Velocity Index &lt;0.25

               4. Aortic valve area (AVA) of ≤ 1.0 cm2 or indexed EOA ≤ 0.6 cm2/m2).

          5. Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional
             Classification of Class II, or greater or other symptoms of aortic stenosis (e.g.
             syncope).

          6. Subject is deemed high operable risk and preferred TAVI delivery route is alternate
             access (subclavian/axillary or direct aortic) per the medical opinion of the center's
             heart team and confirmed by SSC.

               -  High risk is defined as an STS mortality &gt; 8% or documented heart team agreement
                  ≥ high risk for SAVR due to frailty or co-morbidities

        Exclusion Criteria:

          1. Subject is unwilling or unable to comply with all study-required follow-up
             evaluations.

          2. Subject has a documented history of a cerebral vascular accident (CVA) or transient
             ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the
             index procedure.

          3. Subject has carotid artery disease requiring intervention.

          4. Subject has evidence of a myocardial infarction (MI) within 30 days prior to patient
             index procedure.

          5. Subject has a native aortic valve that is congenitally unicuspid, bicuspid,
             quadricuspid or non-calcified as seen by echocardiography.

          6. Subject has severe mitral valvular regurgitation.

          7. Subject has severe mitral stenosis.

          8. Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any
             position.

          9. Subject refuses any blood product transfusion.

         10. Subject has resting left ventricular ejection fraction (LVEF) less than 20%.

         11. Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring
             revascularization.

         12. Subject has had a percutaneous interventional or other invasive cardiovascular or
             peripheral vascular procedure less than or equal to 14 days prior to index procedure.

         13. Subject has severe basal septal hypertrophy that would interfere with transcatheter
             aortic valve placement.

         14. Subject has a history of, or is currently diagnosed with, endocarditis.

         15. There is imaging evidence of intracardiac mass, thrombus, or vegetation.

         16. Subject is considered hemodynamically unstable (requiring inotropic support or
             mechanical heart assistance).

         17. Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to
             stabilize heart failure.

         18. Subject with severe pulmonary disease as determined by STS score.

         19. Subject is on chronic oral steroid therapy.

         20. Subject has a documented hypersensitivity or contraindication to anticoagulant or
             antiplatelet medication.

         21. Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0
             mg/dL (265.5 µmol/L) or end-stage renal disease requiring chronic dialysis.

         22. Subject has morbid obesity defined as a BMI greater than or equal to 40.

         23. Subject has ongoing infection or sepsis.

         24. Subject has uncontrolled blood dyscrasias as defined: leukopenia (WBC&lt;3000 mm3), acute
             anemia (Hb&lt;9 mg/dL), thrombocytopenia (platelet count &lt;50,000 cells/mm3,).

         25. Anatomy falling outside the recommended values in the IFU, unless specifically
             approved by the Subject Selection Committee.

         26. Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90
             days prior to the index procedure.

         27. Subject is currently participating in another investigational drug or device study,
             unless approved by the Sponsor.

         28. Subject has/had emergency surgery for any reason within 30 days of the index
             procedure.

         29. Subject has a life expectancy less than 1 year.

         30. Subject has other medical, social or psychological conditions that, in the opinion of
             the Principal Investigator or the Subject Selection Committee, preclude the subject
             from study participation.

         31. Subject is diagnosed with a state of dementia which would fundamentally complicate
             rehabilitation from the procedure or compliance with follow-up visits.

         32. Subject has a documented allergy to contrast media that cannot adequately be treated,
             nitinol alloys, porcine tissue, or bovine tissue.

         33. Significant aortic disease including abdominal aortic or thoracic aneurysm defined as
             maximal luminal diameter 5cm or greater

         34. Subjects with severe pulmonary hypertension and severe RV dysfunction

         35. Subjects with hypertrophic cardiomyopathy

        Transaortic Subject Cohort Specific Exclusion Criteria

        Subjects are not eligible for participation in the TAo access arm if they meet any of the
        following exclusion criteria:

          1. Subject has a chest condition (anatomical or otherwise) that prevents TAo access.

          2. Subject has pre-existing patent RIMA graft that would preclude access.

          3. Subject has a porcelain aorta, defined as an extensive circumferential calcification
             of the ascending aorta that would complicate TAo access.

        Subclavian/Axillary Subject Cohort Specific Exclusion Criteria

        Subjects are not eligible for participation in the subclavian/axillary access arm if they
        meet any of the following exclusion criteria:

          1. Subject's access vessel (subclavian/axillary) diameter will not allow for introduction
             of the 18/19 Fr delivery system.

          2. Subject's subclavian/axillary arteries have severe calcification and/or tortuosity.

          3. Subject has a history of LIMA/RIMA graft that would preclude access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen Medizinische Klinik-Kardio</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Ca'Granda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam Academic Medical Centre (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basel University Hospital</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <results_first_submitted>January 9, 2020</results_first_submitted>
  <results_first_submitted_qc>March 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 17, 2020</results_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>Valvular heart disease</keyword>
  <keyword>Transcatheter aortic valve implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03056573/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 64 subjects were enrolled and undergone implant with a Portico Transcatheter Aortic Valve via an alternative access route at 10 sites between March 29, 2017 and June 04, 2018.</recruitment_details>
      <pre_assignment_details>Of the 64 subjects, 45 subjects were implanted via subclavian/axillary access and 19 via transaortic access. Enrollment in the transaortic arm was stopped after 15 months due to a slow enrollment rate. All subjects will be followed through 1-year post implant.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subclavian/Axillary Access Arm</title>
          <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
        </group>
        <group group_id="P2">
          <title>Transaortic Access Arm</title>
          <description>Subjects who underwent Transaortic TAVR implant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subclavian/Axillary Access Arm</title>
          <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
        </group>
        <group group_id="B2">
          <title>Transaortic Arm</title>
          <description>Subjects who underwent Transaortic TAVR implant.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.7" spread="5.9"/>
                    <measurement group_id="B2" value="77.1" spread="7.2"/>
                    <measurement group_id="B3" value="80.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Major Vascular Complications</title>
        <description>Major Vascular complication is defined as
Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudo-aneurysm or
Access site or access-related vascular injury leading to death, life-threatening or major bleeding, visceral ischaemia or neurological impairment or
Distal embolization from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage or
The use of unplanned endovascular or surgical intervention associated with death, major bleeding, visceral ischaemia or neurological impairment or
Any new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram or
Surgery for access site-related nerve injury or
Permanent access site-related nerve injury</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Vascular Complications</title>
          <description>Major Vascular complication is defined as
Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudo-aneurysm or
Access site or access-related vascular injury leading to death, life-threatening or major bleeding, visceral ischaemia or neurological impairment or
Distal embolization from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage or
The use of unplanned endovascular or surgical intervention associated with death, major bleeding, visceral ischaemia or neurological impairment or
Any new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram or
Surgery for access site-related nerve injury or
Permanent access site-related nerve injury</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All- Cause Mortality</title>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All- Cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All- Cause Mortality</title>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All- Cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Mortality</title>
        <description>Any 1 of the following criteria:
Death due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, worsening heart failure)
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease.
All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure
All valve-related deaths including structural or nonstructural valve dysfunction or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Mortality</title>
          <description>Any 1 of the following criteria:
Death due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, worsening heart failure)
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease.
All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure
All valve-related deaths including structural or nonstructural valve dysfunction or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Mortality</title>
        <description>Any 1 of the following criteria:
Death due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, worsening heart failure)
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease.
All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure
All valve-related deaths including structural or nonstructural valve dysfunction or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Mortality</title>
          <description>Any 1 of the following criteria:
Death due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, worsening heart failure)
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease.
All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure
All valve-related deaths including structural or nonstructural valve dysfunction or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Disabling Stroke</title>
        <description>Disabling stroke is an mRS score of 2 or more at 90 days and an increase of at least 1 mRS category from an individual's prestroke baseline</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disabling Stroke</title>
          <description>Disabling stroke is an mRS score of 2 or more at 90 days and an increase of at least 1 mRS category from an individual's prestroke baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Disabling Stroke</title>
        <description>Disabling stroke is an mRS score of 2 or more at 90 days and an increase of at least 1 mRS category from an individual's prestroke baseline</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disabling Stroke</title>
          <description>Disabling stroke is an mRS score of 2 or more at 90 days and an increase of at least 1 mRS category from an individual's prestroke baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-disabling Strokes</title>
        <description>Non-disabling is an mRS score of &lt;2 at 90 days or 1 that does not result in an increase of at least 1 mRS category from an individual's prestroke baseline</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-disabling Strokes</title>
          <description>Non-disabling is an mRS score of &lt;2 at 90 days or 1 that does not result in an increase of at least 1 mRS category from an individual's prestroke baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-disabling Strokes</title>
        <description>Non-disabling is an mRS score of &lt;2 at 90 days or 1 that does not result in an increase of at least 1 mRS category from an individual's prestroke baseline</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-disabling Strokes</title>
          <description>Non-disabling is an mRS score of &lt;2 at 90 days or 1 that does not result in an increase of at least 1 mRS category from an individual's prestroke baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Life Threatening Bleeding Requiring Transfusion</title>
        <description>Life threatening bleeding requiring transfusion
Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0 g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery AND
Does not meet criteria of life-threatening or disabling bleeding</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Life Threatening Bleeding Requiring Transfusion</title>
          <description>Life threatening bleeding requiring transfusion
Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0 g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery AND
Does not meet criteria of life-threatening or disabling bleeding</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Life Threatening Bleeding Requiring Transfusion</title>
        <description>Life threatening bleeding requiring transfusion
Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0 g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery AND
Does not meet criteria of life-threatening or disabling bleeding</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Life Threatening Bleeding Requiring Transfusion</title>
          <description>Life threatening bleeding requiring transfusion
Overt bleeding either associated with a drop in the hemoglobin level of at least 3.0 g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery AND
Does not meet criteria of life-threatening or disabling bleeding</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Kidney Injury Requiring Dialysis</title>
        <description>Increase in serum creatinine to greater than or equal to 300% (3 X increase compared with baseline) or serum creatinine of ≥ 4.0 mg/dL (354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)or Urine output &lt;0.3 mL/kg per hour for ≥24 hours or anuria for ≥12 hours. Patients receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Kidney Injury Requiring Dialysis</title>
          <description>Increase in serum creatinine to greater than or equal to 300% (3 X increase compared with baseline) or serum creatinine of ≥ 4.0 mg/dL (354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)or Urine output &lt;0.3 mL/kg per hour for ≥24 hours or anuria for ≥12 hours. Patients receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Kidney Injury Requiring Dialysis</title>
        <description>Increase in serum creatinine to greater than or equal to 300% (3 X increase compared with baseline) or serum creatinine of ≥ 4.0 mg/dL (354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)or Urine output &lt;0.3 mL/kg per hour for ≥24 hours or anuria for ≥12 hours. Patients receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Kidney Injury Requiring Dialysis</title>
          <description>Increase in serum creatinine to greater than or equal to 300% (3 X increase compared with baseline) or serum creatinine of ≥ 4.0 mg/dL (354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)or Urine output &lt;0.3 mL/kg per hour for ≥24 hours or anuria for ≥12 hours. Patients receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of Periprocedural Encephalopathy, All Stroke and All TIA</title>
        <description>Stroke is an acute symptomatic episode of neurological dysfunction attributed to a vascular cause.
Transient Ischemic Attack (TIA) is a transient (less than 24 hrs) episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. No evidence of infarction if imaging performed.
Encephalopathy is defined as altered mental state (e.g., seizures, delirium, confusion, hallucinations, dementia, coma, psychiatric episode).</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Periprocedural Encephalopathy, All Stroke and All TIA</title>
          <description>Stroke is an acute symptomatic episode of neurological dysfunction attributed to a vascular cause.
Transient Ischemic Attack (TIA) is a transient (less than 24 hrs) episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. No evidence of infarction if imaging performed.
Encephalopathy is defined as altered mental state (e.g., seizures, delirium, confusion, hallucinations, dementia, coma, psychiatric episode).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of Periprocedural Encephalopathy, All Stroke and All TIA</title>
        <description>Stroke is an acute symptomatic episode of neurological dysfunction attributed to a vascular cause.
Transient Ischemic Attack (TIA) is a transient (less than 24 hrs) episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. No evidence of infarction if imaging performed.
Encephalopathy is defined as altered mental state (e.g., seizures, delirium, confusion, hallucinations, dementia, coma, psychiatric episode).</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Periprocedural Encephalopathy, All Stroke and All TIA</title>
          <description>Stroke is an acute symptomatic episode of neurological dysfunction attributed to a vascular cause.
Transient Ischemic Attack (TIA) is a transient (less than 24 hrs) episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. No evidence of infarction if imaging performed.
Encephalopathy is defined as altered mental state (e.g., seizures, delirium, confusion, hallucinations, dementia, coma, psychiatric episode).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate and Severe Aortic Regurgitation</title>
        <time_frame>1 year</time_frame>
        <population>The number of participants who were available at that time point were included</population>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate and Severe Aortic Regurgitation</title>
          <population>The number of participants who were available at that time point were included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NYHA Class From Baseline to 30 Days</title>
        <description>New York Heart Association (NYHA) functional classification provides a way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina pain.
Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest.</description>
        <time_frame>Baseline to 30 days</time_frame>
        <population>We had presented the data only for the participants who had an outcome at baseline and at 30 days (paired data).</population>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NYHA Class From Baseline to 30 Days</title>
          <description>New York Heart Association (NYHA) functional classification provides a way of classifying the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina pain.
Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest.</description>
          <population>We had presented the data only for the participants who had an outcome at baseline and at 30 days (paired data).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improvement from Baseline (BL) NYHA I to 30days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement from BL NYHA II to 30days NYHA I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement from BL NYHA III to 30days NYHA I &amp; II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement fromBL NYHA IV to 30days NYHA I,II,III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Six Minute Walk Test From Baseline as Compared to 30 Days</title>
        <description>The Six Minute Walk Test (6MWT)measures the distance that a patient can walk in a period of 6 minutes. The distance walked is measured in meters. This test measures the patients' functional status. The more meters a patient can walk over baseline indicates improvement in functional status.</description>
        <time_frame>Baseline to 30 days</time_frame>
        <population>We had presented the data only for the participants who had an outcome at baseline and at 30 days (paired data).</population>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Six Minute Walk Test From Baseline as Compared to 30 Days</title>
          <description>The Six Minute Walk Test (6MWT)measures the distance that a patient can walk in a period of 6 minutes. The distance walked is measured in meters. This test measures the patients' functional status. The more meters a patient can walk over baseline indicates improvement in functional status.</description>
          <population>We had presented the data only for the participants who had an outcome at baseline and at 30 days (paired data).</population>
          <units>Meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" spread="94.7"/>
                    <measurement group_id="O2" value="6.0" spread="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Effective Orifice Area From Baseline as Compared to 30 Days</title>
        <description>Effective Orifice Area of the prosthetic valve measured via echocardiography to determine physiological area of blood flow through the valve.</description>
        <time_frame>Baseline to 30 days.</time_frame>
        <population>We had presented the data only for the participants who had an outcome at baseline and at 30 days (paired data).</population>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Effective Orifice Area From Baseline as Compared to 30 Days</title>
          <description>Effective Orifice Area of the prosthetic valve measured via echocardiography to determine physiological area of blood flow through the valve.</description>
          <population>We had presented the data only for the participants who had an outcome at baseline and at 30 days (paired data).</population>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.3"/>
                    <measurement group_id="O2" value="1.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Acute Device Success</title>
        <description>Acute device success is defined as a subject who achieves a) successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system, b) correct position of the device in the proper anatomical location, c) intended performance of the prosthetic heart valve, and d) only 1 valve implanted in the proper anatomical location.
Device success is a 'technical' composite endpoint meant to characterize the acute device and procedural factors which underlie vascular access, delivery, and performance of the TAVI system. Echocardiography should be routinely utilized as the standard for measuring prosthetic valve stenosis and regurgitation immediately after TAVI, and should always be performed in a resting state, either within 24-48 h after the index procedure or before hospital discharge.</description>
        <time_frame>7 days</time_frame>
        <population>The number of participants who were available at that time point were included</population>
        <group_list>
          <group group_id="O1">
            <title>Subclavian/Axillary Access Arm</title>
            <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
          </group>
          <group group_id="O2">
            <title>Transaortic Access Arm</title>
            <description>Subjects who underwent Transaortic TAVR implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Acute Device Success</title>
          <description>Acute device success is defined as a subject who achieves a) successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system, b) correct position of the device in the proper anatomical location, c) intended performance of the prosthetic heart valve, and d) only 1 valve implanted in the proper anatomical location.
Device success is a 'technical' composite endpoint meant to characterize the acute device and procedural factors which underlie vascular access, delivery, and performance of the TAVI system. Echocardiography should be routinely utilized as the standard for measuring prosthetic valve stenosis and regurgitation immediately after TAVI, and should always be performed in a resting state, either within 24-48 h after the index procedure or before hospital discharge.</description>
          <population>The number of participants who were available at that time point were included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subclavian/Axillary Access Arm</title>
          <description>Subjects who underwent TAVR with the Portico THV via the subclavian or axillary alternative access site.</description>
        </group>
        <group group_id="E2">
          <title>Transaortic Access Arm</title>
          <description>Subjects who underwent Transaortic TAVR implant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chronic Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Complete Heart Block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Left Bundle Branch Block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pericardial Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Reduced Left Ventricular Function/ Subclinical Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death of unknown cause</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Increasing Pain On Both Legs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Access Site Bleeding Event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Broken Arm Right Side</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Broken Left Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Broken Leg With Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cardiac Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Femoral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Re-Fracture Left Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vascular Access Site and Access Related Complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack (TIA)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Device Embolization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vessel Dissection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Complete Heart Block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>First Degree Heart Block</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Left Bundle Branch Block</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Right Bundle Branch Block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Accelerated Junctional Rhythm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mild Congestive Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Supraventricular Extrasystole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Transient LBBB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Left Anterior Fascicular Block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness And Short-Term Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Access Site Bleeding Event</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vessel Dissection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Painful Right Groin (Diagnostic Site)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pinched Nerve</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain Shoulder Left Access Site Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Painful Left Arm (With Impaired Mobility)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Syncope Epileptic Insult</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Insufficiency/Worsening Renal Function</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angelic Roach, Clinical Program Director</name_or_title>
      <organization>Abbott</organization>
      <phone>+16517563379</phone>
      <email>angelic.roach@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

